Zolpax Nasal Spray contains Zolmitriptan. Zolpax Nasal Spray uses:

Zolpax Nasal Spray is indicated for the treatment of acute migraine with or without aura in adults.

Brand Name: Zolpax Nasal Spray
Generic: Zolmitriptan
Weight: 5.0 Mg
Type: Nasal Spray
Therapeutic Class: 5-HT Agonists
Price: 414.8
Last Updated: 2020-11-20 18:15:00


Zolpax Nasal Spray contains Zolmitriptan 5.0 Mg. Zolpax Nasal Spray doses

The recommended dose of Zolpax Nasal Spray to treat a migraine attack is 2.5 mg. If symptoms persist or return within 24 hours, a second dose has been shown to be effective, but it should not be taken within 2 hours of the initial dose. If a patient does not achieve satisfactory relief with 2.5 mg doses, subsequent attacks can be treated with 5 mg initial doses of Zolpax Nasal Spray. In those patients who respond, significant efficacy is apparent within 1 hour of dosing. Zolpax Nasal Spray is equally effective whenever the tablets are taken during a migraine attack, although it is advisable that Zolpax Nasal Spray tablets are taken as early as possible after the onset of migraine headache.Zolpax Nasal Spray is not indicated for prophylaxis of migraine. In the event of recurrent attacks, it is recommended that the total intake of Zolpax Nasal Spray in a 24 hour period should not exceed 10 mg.


Side Effects

Zolpax Nasal Spray is generally well tolerated. Adverse reactions are typically mild/moderate, transient, not serious and resolve spontaneously without additional treatment. Possible adverse reactions tend to occur within 4 hours of administration and are not more frequent following repeated dosing. The following adverse reactions have been the most commonly reported: nausea, dizziness, somnolence, warm sensation, asthenia and dry mouth. Abnormalities or disturbances of sensation have been reported, heaviness, tightness or pressure may occur in the throat, neck, limbs and chest (with no evidence of ischaemic changes on ECG) as may myalgia, muscle weakness, paraesthesia and dysesthesia.


Zolpax Nasal Spray is an antimigraine agent. It binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of Zolpax Nasal Spray for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system which results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Zolpax Nasal Spray is rapidly and well absorbed after oral administration.


Zolpax Nasal Spray should only be used where a clear diagnosis of migraine has been established. Care should be taken to exclude other potentially serious neurological conditions. There are no data on the use of Zolpax Nasal Spray in haemiplegic or basilar migraine. Zolpax Nasal Spray should not be given to patients with Wolff Parkinson White syndrome or arrhythmias associated with other accessory cardiac condition pathways. This class of compounds (5HT1D agonists) has been associated with coronary vasospasm; as a result, patients with ischaemic heart disease were excluded from clinical trials. Zolpax Nasal Spray is therefore, not recommended in this patient group. In patients in whom unrecognised coronary artery disease is likely, cardiovascular evaluation prior to commencement of treatment with 5HT1D agonists is recommended. As with other 5HT1D agonists, atypical sensations over the pericardium have been reported after the administration of Zolpax Nasal Spray, but in clinical trials these have not been associated with arrhythmias or ischaemic changes on ECG. Zolpax Nasal Spray may cause mild, transient increases in blood pressure (which may be more pronounced in the elderly), however this has not been associated with clinical sequelae in the clinical trial programme.


From studies there is no evidence that concomitant use of migraine prophylactic medications (for example b blockers, oral dihydroergotamine, Pizotifen) has any effect on the efficacy or unwanted effects of Zolpax Nasal Spray. The pharmacokinetics and tolerability of Zolpax Nasal Spray oral tablets were unaffected by acute symptomatic treatments such as Paracetamol, Metoclopramide and Ergotamine. Concomitant administration of other 5HT1B/1D agonists within 12 hours of Zolpax Nasal Spray treatment should be avoided. Data from healthy subjects suggest that there are no pharmacokinetic or clinically significant interactions between Zolpax Nasal Spray and Ergotamine, however, the increased risk of coronary vasospasm is a theoretical possibility.Therefore, it is advised to wait at least 24 hours following the use of Ergotamine containing preparations before administering Zolmit. Conversely it is advised to wait at least six hours following use of Zolpax Nasal Spray before administering any Ergotamine preparation. A maximum intake of 5 mg Zolpax Nasal Spray nasal spray in 24 hours is recommended in patients taking an MAO inhibitor, general P450 inhibitor. Fluoxetine does not affect the pharmacokinetic parameters of Zolpax Nasal Spray. Therapeutic doses of the selective serotonin reuptake inhibitors (SSRIs), Fluoxetine, Sertraline, Paroxetine and Citalopram do not inhibit CYP1A2.

Pregnancy Lactation use

Pregnancy: Zolpax Nasal Spray should be used in pregnancy only if the benefits to the mother justify potential risk to the foetus.Lactation: Studies have shown that Zolpax Nasal Spray passes into the milk of lactating animals. No data exist in lactating women. Therefore, caution should be exercised when administering Zolpax Nasal Spray to lactating women.


Zolpax Nasal Spray is contraindicated in patients with :

  • Known hypersensitivity to any component of the product
  • Uncontrolled hypertension
  • Ischaemic heart disease
  • Coronary vasospasm/Prinzmetal’s angina
  • A history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA)
Special Warning

Use in children: Safety and efficacy of Zolpax Nasal Spray in paediatric patients have not been established.Use in patients aged over 65 years: Safety and efficacy of Zolpax Nasal Spray in individuals aged over 65 years have not been systematically evaluated.Patients with hepatic impairment: The dose of Zolpax Nasal Spray should be reduced in patients with moderate to severe hepatic impairment, maximum dose of 5 mg in 24 hours is recommended. Patients with renal impairment: No dosage adjustment is required.

Acute Overdose


Interaction with other Medicine


Storage Condition

Keep out of the reach of children. Store at a cool and dry place. Protect from light and moisture.

Zolpax Nasal Spray Nasal Spray price in India 414.8